Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 137 citing articles:

Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Kamran Ghoreschi, Anna Balato, Charlotta Enerbäck, et al.
The Lancet (2021) Vol. 397, Iss. 10275, pp. 754-766
Closed Access | Times Cited: 404
Comparison of Biologics and Oral Treatments for Plaque Psoriasis
April W. Armstrong, L. Puig, Avani Joshi, et al.
JAMA Dermatology (2020) Vol. 156, Iss. 3, pp. 258-258
Open Access | Times Cited: 215
Interleukin-17A and Keratinocytes in Psoriasis
Masutaka Furue, Kazuhisa Furue, Gaku Tsuji, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 4, pp. 1275-1275
Open Access | Times Cited: 213
Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review
Masahiro Kamata, Yayoi Tada
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 5, pp. 1690-1690
Open Access | Times Cited: 180
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*
Richard B. Warren, Andrew Blauvelt, Yves Poulin, et al.
British Journal of Dermatology (2020) Vol. 184, Iss. 1, pp. 50-59
Open Access | Times Cited: 155
Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review
Kevin Yang, Allen S. W. Oak, Boni E. Elewski
American Journal of Clinical Dermatology (2020) Vol. 22, Iss. 2, pp. 173-192
Open Access | Times Cited: 144
The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Rohan Singh, Sindhuja Koppu, Patrick O. Perche, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 12793-12793
Open Access | Times Cited: 109
The role of inflammation in autoimmune disease: a therapeutic target
Yu Xiang, Mingxue Zhang, D.Y. Jiang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 52
Systemic Treatment of Psoriasis with JAK Inhibitors: A Review
Amanda Kvist‐Hansen, Peter Riis Hansen, Lone Skov
Dermatology and Therapy (2019) Vol. 10, Iss. 1, pp. 29-42
Open Access | Times Cited: 106
Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis
Satveer K. Mahil, Martinsixtus Ezejimofor, L.S. Exton, et al.
British Journal of Dermatology (2020) Vol. 183, Iss. 4, pp. 638-649
Open Access | Times Cited: 77
Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 3, pp. 885-905
Open Access | Times Cited: 62
Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics
Hakim Ben Abdallah, Claus Johansen, Lars Iversen
Psoriasis Targets and Therapy (2021) Vol. Volume 11, pp. 83-97
Open Access | Times Cited: 58
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes
Iain B. McInnes, L. Sawyer, Kristen Markus, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002074-e002074
Open Access | Times Cited: 48
Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion
H. Bachelez, Juliet N. Barker, A. David Burden, et al.
Expert Review of Clinical Immunology (2022) Vol. 18, Iss. 10, pp. 1033-1047
Open Access | Times Cited: 47
The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis – A network meta‐analysis
Lu Zhang, Lei Guo, Lin Wang, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 11, pp. 1937-1946
Closed Access | Times Cited: 43
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
April W. Armstrong, Kyle Fahrbach, Craig L. Leonardi, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 8, pp. 1777-1792
Open Access | Times Cited: 41
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
Susanne Klint, Joachim Feldwisch, Lindvi Gudmundsdotter, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 33
Potential Therapeutic Value of the STING Inhibitors
Shangran Zhang, Runan Zheng, Yanhong Pan, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3127-3127
Open Access | Times Cited: 23
The role of IL‐23 and the use of IL‐23 inhibitors in psoriatic arthritis
G. Fragoulis, Stefan Siebert
Musculoskeletal Care (2022) Vol. 20, Iss. S1
Open Access | Times Cited: 28
Ixekizumab for the treatment of psoriasis: up-to-date
Sarah Craig, Richard B. Warren
Expert Opinion on Biological Therapy (2020) Vol. 20, Iss. 6, pp. 549-557
Closed Access | Times Cited: 49
Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, et al.
Dermatology and Therapy (2021) Vol. 12, Iss. 1, pp. 167-184
Open Access | Times Cited: 36
Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis
Cristina Membrive-Jiménez, Cristina Pérez-Ramírez, Almudena Sánchez Martín, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 4, pp. 293-293
Open Access | Times Cited: 33
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)
Andreas Pinter, L. Puig, Knut Schäkel, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 11, pp. 2087-2100
Open Access | Times Cited: 27
Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis
Eugenia Piragine, Davide Petri, Alma Martelli, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 6, pp. 1506-1506
Open Access | Times Cited: 25
Novel Therapeutic Target(s) for Psoriatic Disease
Vishal Thakur, Rahul Mahajan
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top